PREDILIFE SA (ALPRE.PA) Stock Price & Overview
EPA:ALPRE • FR0010169920
Current stock price
The current stock price of ALPRE.PA is 3.12 EUR. Today ALPRE.PA is down by 0%. In the past month the price increased by 0.97%. In the past year, price decreased by -18.75%.
ALPRE.PA Key Statistics
- Market Cap
- 12.262M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.99
- Dividend Yield
- N/A
ALPRE.PA Stock Performance
ALPRE.PA Stock Chart
ALPRE.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALPRE.PA. When comparing the yearly performance of all stocks, ALPRE.PA is a bad performer in the overall market: 85.73% of all stocks are doing better.
ALPRE.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALPRE.PA. ALPRE.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ALPRE.PA Earnings
ALPRE.PA Forecast & Estimates
9 analysts have analysed ALPRE.PA and the average price target is 21.34 EUR. This implies a price increase of 583.92% is expected in the next year compared to the current price of 3.12.
For the next year, analysts expect an EPS growth of -10.83% and a revenue growth 50.7% for ALPRE.PA
ALPRE.PA Groups
Sector & Classification
ALPRE.PA Financial Highlights
Over the last trailing twelve months ALPRE.PA reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 20.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -290.42% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALPRE.PA Ownership
ALPRE.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 24.31 | 36.326B | ||
| ARGX | ARGENX SE | 24.22 | 36.189B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.299B | ||
| ABVX | ABIVAX SA | N/A | 8.651B | ||
| 2X1 | ABIVAX SA | N/A | 8.556B | ||
| GXE | GALAPAGOS NV | N/A | 1.827B | ||
| GLPG | GALAPAGOS NV | N/A | 1.824B | ||
| NANO | NANOBIOTIX | N/A | 1.248B | ||
| 6IV | INVENTIVA SA | N/A | 1.094B | ||
| IVA | INVENTIVA SA | N/A | 1.061B | ||
| PHIL | PHILOGEN SPA | 18.49 | 675.444M | ||
| XUP | GENFIT | 917.65 | 468.027M | ||
| GNFT | GENFIT | 855.88 | 436.525M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALPRE.PA
Company Profile
Predilife SA operates as a medical technology company. The company is headquartered in Villejuif, Ile-De-France and currently employs 27 full-time employees. The company went IPO on 2018-12-21. The firm operates mainly in the field of oncology. Predilife offers MammoRisk, which is a predictive breast cancer test that combines medical imaging thanks to a proprietary software, DenSeeMammo, Big Data and statistics through a scoring tool and genetic profiles via a polygenic risk score (PRS). The image is analysed in order to extract the breast density and the first breast cancer risk factor. In addition, The technology used by MammoRisk makes it possible to evaluate from a database of individuals tracked over time, the risks of an individual to develop cancer compared to the fate of his/her closest neighbors through a database of a number of American and French women.
Company Info
IPO: 2018-12-21
PREDILIFE SA
Igr Campus Cancer 1 Batiment Maurice, 39 Rue Camille Desmoulins
Villejuif ILE-DE-FRANCE FR
Employees: 27
Phone: 33142114211.0
PREDILIFE SA / ALPRE.PA FAQ
Can you describe the business of PREDILIFE SA?
Predilife SA operates as a medical technology company. The company is headquartered in Villejuif, Ile-De-France and currently employs 27 full-time employees. The company went IPO on 2018-12-21. The firm operates mainly in the field of oncology. Predilife offers MammoRisk, which is a predictive breast cancer test that combines medical imaging thanks to a proprietary software, DenSeeMammo, Big Data and statistics through a scoring tool and genetic profiles via a polygenic risk score (PRS). The image is analysed in order to extract the breast density and the first breast cancer risk factor. In addition, The technology used by MammoRisk makes it possible to evaluate from a database of individuals tracked over time, the risks of an individual to develop cancer compared to the fate of his/her closest neighbors through a database of a number of American and French women.
What is the current price of ALPRE stock?
The current stock price of ALPRE.PA is 3.12 EUR.
Does PREDILIFE SA pay dividends?
ALPRE.PA does not pay a dividend.
How is the ChartMill rating for PREDILIFE SA?
ALPRE.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of ALPRE stock?
PREDILIFE SA (ALPRE.PA) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for ALPRE stock?
PREDILIFE SA (ALPRE.PA) currently has 27 employees.
What is PREDILIFE SA worth?
PREDILIFE SA (ALPRE.PA) has a market capitalization of 12.26M EUR. This makes ALPRE.PA a Nano Cap stock.